---
layout: default
---

# Configurations

| UniProt Accession Number   | Reagent Type     | Target Name / Protein Biomarker   | Target Species   | Host Organism   | Isotype   | Clonality   | Vendor    |   Catalog Number | Conjugate    | RRID       | Availability   | Method        | Tissue Preservation   | Target Tissue   | Tissue State   | Detergent         | Antigen Retrieval Conditions                                                               | Dye Inactivation Conditions   | Recommend   | Agree               | Disagree   | Contributor         | Notes       |
|:---------------------------|:-----------------|:----------------------------------|:-----------------|:----------------|:----------|:------------|:----------|-----------------:|:-------------|:-----------|:---------------|:--------------|:----------------------|:----------------|:---------------|:------------------|:-------------------------------------------------------------------------------------------|:------------------------------|:------------|:--------------------|:-----------|:--------------------|:------------|
| P01732                     | Primary Antibody | CD8                               | Human            | Mouse           | IgG1      | C8/144B     | BioLegend |           372910 | Spark YG 570 | AB_2904405 | Stock          | IBEX2D Manual | FFPE                  | Tonsil          | NA             | 0.3% Triton-X-100 | pH 6 for 30 minutes ER1 (AF9961) and pH 9 for 30 minutes ER2 (AF9640) using the Leica Bond | NA                            | Yes         | [0000-0003-4379-8967](https://orcid.org/0000-0003-4379-8967) | NA         | [0000-0003-4379-8967](https://orcid.org/0000-0003-4379-8967) | [1](#notes) |

# Publications



# Additional Notes

<a name="notes"></a>
1. Labels cytotoxic T cells in FFPE tonsil tissues. Antibody yields a great signal; however, the Spark YG570 conjugate does not dye inactivate within 15 minutes of 1 mg/ml LiBH4 treatment. Additional dye inactivation conditions need to be tested. This antibody could be placed in the last cycle or used as a fiducial.
